Bausch Health Companies Inc Cash Flow Conversion Efficiency
Bausch Health Companies Inc cash flow conversion efficiency. Based on the latest financial reports, Bausch Health Companies Inc (BHC) has a cash flow conversion efficiency ratio of -0.835x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$670.00 Million ≈ $484.67 Million USD) by net assets (CA$-802.00 Million ≈ $-580.15 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Bausch Health Companies Inc for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Bausch Health Companies Inc (1993–2025)
Cash flow conversion efficiency of Bausch Health Companies Inc from 1993 to 2025. This chart illustrates how Bausch Health Companies Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Bausch Health Companies Inc stock quote for real-time trading data and today's change.
Bausch Health Companies Inc Cash Flow Conversion Ratio Explained
Bausch Health Companies Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Bausch Health Companies Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bausch Health Companies Inc ranked by their cash flow conversion efficiency. Review Bausch Health Companies Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Berner Kantonalbank AG
SW:BEKN
|
0.136x |
|
Enliven Therapeutics Inc.
NASDAQ:ELVN
|
-0.021x |
|
Curbline Properties Corp.
NYSE:CURB
|
0.023x |
|
Apeloa Pharmaceutical Co Ltd
SHE:000739
|
0.068x |
|
BW LPG Limited
NYSE:BWLP
|
0.078x |
|
Sparebank 1 SMN
OL:MING
|
0.005x |
|
Guangdong Electric Power Development Co Ltd
SHE:000539
|
0.059x |
|
Adecco Group AG
F:ADIA
|
0.140x |
Annual Cash Flow Conversion Efficiency for Bausch Health Companies Inc (1993–2025)
The table below shows the annual cash flow conversion efficiency of Bausch Health Companies Inc from 1993 to 2025. Also see BHC total assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$376.31 Million ≈ $272.22 Million |
CA$1.38 Billion ≈ $997.34 Million |
3.664x | +173.87% |
| 2024-12-31 | CA$-322.00 Million ≈ $-232.93 Million |
CA$1.60 Billion ≈ $1.16 Billion |
-4.960x | +60.59% |
| 2023-12-31 | CA$-82.00 Million ≈ $-59.32 Million |
CA$1.03 Billion ≈ $746.53 Million |
-12.585x | -349.48% |
| 2022-12-31 | CA$260.00 Million ≈ $188.08 Million |
CA$-728.00 Million ≈ $-526.62 Million |
-2.800x | +93.32% |
| 2021-12-31 | CA$-34.00 Million ≈ $-24.60 Million |
CA$1.43 Billion ≈ $1.03 Billion |
-41.941x | -2383.93% |
| 2020-12-31 | CA$605.00 Million ≈ $437.65 Million |
CA$1.11 Billion ≈ $803.68 Million |
1.836x | +38.98% |
| 2019-12-31 | CA$1.14 Billion ≈ $821.77 Million |
CA$1.50 Billion ≈ $1.09 Billion |
1.321x | +147.80% |
| 2018-12-31 | CA$2.81 Billion ≈ $2.04 Billion |
CA$1.50 Billion ≈ $1.09 Billion |
0.533x | +38.40% |
| 2017-12-31 | CA$5.94 Billion ≈ $4.30 Billion |
CA$2.29 Billion ≈ $1.66 Billion |
0.385x | -39.86% |
| 2016-12-31 | CA$3.26 Billion ≈ $2.36 Billion |
CA$2.09 Billion ≈ $1.51 Billion |
0.641x | +75.54% |
| 2015-12-31 | CA$6.03 Billion ≈ $4.36 Billion |
CA$2.20 Billion ≈ $1.59 Billion |
0.365x | -13.58% |
| 2014-12-31 | CA$5.43 Billion ≈ $3.93 Billion |
CA$2.29 Billion ≈ $1.66 Billion |
0.422x | +112.08% |
| 2013-12-31 | CA$5.23 Billion ≈ $3.79 Billion |
CA$1.04 Billion ≈ $753.74 Million |
0.199x | +12.73% |
| 2012-12-31 | CA$3.72 Billion ≈ $2.69 Billion |
CA$656.58 Million ≈ $474.96 Million |
0.177x | +4.62% |
| 2011-12-31 | CA$4.01 Billion ≈ $2.90 Billion |
CA$676.47 Million ≈ $489.35 Million |
0.169x | +215.02% |
| 2010-12-31 | CA$4.91 Billion ≈ $3.55 Billion |
CA$263.19 Million ≈ $190.39 Million |
0.054x | -79.89% |
| 2009-12-31 | CA$1.35 Billion ≈ $979.73 Million |
CA$360.90 Million ≈ $261.07 Million |
0.266x | +56.71% |
| 2008-12-31 | CA$1.20 Billion ≈ $869.22 Million |
CA$204.32 Million ≈ $147.81 Million |
0.170x | -35.25% |
| 2007-12-31 | CA$1.30 Billion ≈ $938.82 Million |
CA$340.85 Million ≈ $246.57 Million |
0.263x | -35.35% |
| 2006-12-31 | CA$1.28 Billion ≈ $929.45 Million |
CA$521.93 Million ≈ $377.56 Million |
0.406x | +12.50% |
| 2005-12-31 | CA$1.38 Billion ≈ $997.94 Million |
CA$498.11 Million ≈ $360.32 Million |
0.361x | +77.00% |
| 2004-12-31 | CA$1.36 Billion ≈ $982.59 Million |
CA$277.09 Million ≈ $200.44 Million |
0.204x | -36.22% |
| 2003-12-31 | CA$881.60 Million ≈ $637.73 Million |
CA$281.98 Million ≈ $203.98 Million |
0.320x | -19.04% |
| 2002-12-31 | CA$845.69 Million ≈ $611.76 Million |
CA$334.10 Million ≈ $241.69 Million |
0.395x | +56.58% |
| 2001-12-31 | CA$1.13 Billion ≈ $814.58 Million |
CA$284.12 Million ≈ $205.53 Million |
0.252x | -41.54% |
| 2000-12-31 | CA$237.46 Million ≈ $171.77 Million |
CA$102.49 Million ≈ $74.14 Million |
0.432x | +131.96% |
| 1999-12-31 | CA$435.30 Million ≈ $314.89 Million |
CA$81.00 Million ≈ $58.59 Million |
0.186x | -82.23% |
| 1998-12-31 | CA$51.20 Million ≈ $37.04 Million |
CA$53.60 Million ≈ $38.77 Million |
1.047x | +1738.12% |
| 1997-12-31 | CA$75.50 Million ≈ $54.62 Million |
CA$4.30 Million ≈ $3.11 Million |
0.057x | +137.53% |
| 1996-12-31 | CA$36.90 Million ≈ $26.69 Million |
CA$-5.60 Million ≈ $-4.05 Million |
-0.152x | -107.12% |
| 1995-12-31 | CA$14.60 Million ≈ $10.56 Million |
CA$31.10 Million ≈ $22.50 Million |
2.130x | +530.85% |
| 1994-12-31 | CA$7.70 Million ≈ $5.57 Million |
CA$2.60 Million ≈ $1.88 Million |
0.338x | -58.19% |
| 1993-12-31 | CA$-2.60 Million ≈ $-1.88 Million |
CA$-2.10 Million ≈ $-1.52 Million |
0.808x | -- |
About Bausch Health Companies Inc
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmac… Read more